AI assistant
NEOGENOMICS INC — Director's Dealing 2025
Jan 16, 2025
32227_dirs_2025-01-16_f1be806b-bf29-40d5-bbfd-45b5fe03449c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2025-01-14
Reporting Person: Olivo Alicia C (EVP, GC & Business Development)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-14 | Restricted Stock Unit | $0 | A | 59382 | Acquired | Common Stock (59382) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 39414 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $19.12 | 2026-09-30 | Common Stock (1046) | 1046 | Direct |
| Stock Option (Right to Buy) | $27.34 | 2027-05-01 | Common Stock (1024) | 1024 | Direct |
| Stock Option (Right to Buy) | $48.99 | 2028-05-01 | Common Stock (516) | 516 | Direct |
| Stock Option (Right to Buy) | $46.10 | 2028-08-01 | Common Stock (1117) | 1117 | Direct |
| Stock Option (Right to Buy) | $9.45 | 2029-05-01 | Common Stock (22222) | 22222 | Direct |
| Stock Option (Right to Buy) | $10.05 | 2029-09-01 | Common Stock (55332) | 55332 | Direct |
| Stock Option (Right to Buy) | $19.65 | 2030-05-11 | Common Stock (36508) | 36508 | Direct |
| Performance Stock Unit | $0 | Common Stock (19508) | 19508 | Direct | |
| Restricted Stock Unit | $0 | Common Stock (13006) | 13006 | Direct | |
| Stock Option (Right to Buy) | $16.45 | 2034-02-23 | Common Stock (42344) | 42344 | Direct |
| Performance Stock Unit | $0 | Common Stock (25330) | 25330 | Direct | |
| Restricted Stock Unit | $0 | Common Stock (25329) | 25329 | Direct |
Footnotes
F1: This balance includes 503 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan ("ESPP"). The shares were acquired in transactions exempt from Section 16b-3. A Form 4 filed on August 5, 2024 included a footnote with reference to 378 ESPP shares having been acquired and a Form 4 filed on August 19, 2024 included a footnote with reference to 125 ESPP shares having been acquired, however those shares were inadvertently not reflected in the balance in Column 5 on those Form 4s. Those shares are now reflected in this balance.
F2: Once vested, the shares of common stock are not subject to expiration.
F3: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date.
F4: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F5: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F10: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F11: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F12: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F13: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F14: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.